Choi, Seong Hye; Park, Kyung Won; Na, Duk L; Han, Hyun Jeong; Kim, Eun-Joo; Shim, Yong S; Lee, Jae-Hong
Current medical research and opinion
2011Jul ; 27 ( 7 ) :1375-83.
PMID : 21561398
ÀúÀÚ »ó¼¼Á¤º¸
Choi, Seong Hye -
Park, Kyung Won -
Na, Duk L -
Han, Hyun Jeong -
Kim, Eun-Joo -
Shim, Yong S -
Lee, Jae-Hong -
ABSTRACT
OBJECTIVE: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer's disease (AD). RESEARCH DESIGN AND
METHODS: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a 10 cm(2) patch for 4 weeks) followed by 16 weeks of memantine plus rivastigmine patch or rivastigmine patch monotherapy. The primary outcome measure was the retention rate at the end of the trial. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. NCT01025466.
RESULTS: Overall, 88 and 84 patients received rivastigmine patch with and without memantine, respectively, and of these, 77 (87.5%) and 70 (83.3%) patients completed the study. The difference in retention rate was not significant (95% confidence interval: -6.3-14.7%). The incidence of adverse events (AEs) (53.4 vs. 50.6%) and discontinuation due to AEs (6.8 vs. 4.8%) were not different between patients with and without memantine. The most frequent AEs were skin irritation in patients with and without memantine (42.0 vs. 34.9%, p = 0.71), but discontinuation due to skin irritation was rare (4.5 vs. 2.4%, p = 0.74). The incidence of gastrointestinal AEs was very low in patients with and without memantine (nausea, 2.3 vs. 1.2%; vomiting, 1.1 vs. 1.2%). The Korean Version of the Cohen Mansfield Agitation Inventory scores favored rivastigmine patch monotherapy at the end of treatment (p = 0.01). Changes in other efficacy measures were similar between the groups. CONCLUSION: There were no significant differences in tolerability and safety between the treatment groups. The combination therapy of memantine plus rivastigmine patch did not show an advantage over rivastigmine patch monotherapy on efficacy analyses. The sample size for comparing tolerability may have been too small to detect a difference of efficacy between the two groups.
Alzheimer's disease, Combination, Memantine, Rivastigmine, Transdermal patch
MESH
Administration, Cutaneous, Aged, Aged, 80 and over, Alzheimer Disease/*drug therapy, Antiparkinson Agents/administration & dosage/adverse effects, Drug Therapy, Combination, Female, Humans, Male, Memantine/*administration & dosage/*adverse effects, Middle Aged, Neuroprotective Agents/administration & dosage/adverse effects, Phenylcarbamates/*administration & dosage/adverse effects, Rivastigmine, Severity of Illness Index, Transdermal Patch, Treatment Outcome
¸µÅ©